Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)

Rhea-AI Summary

Bausch Health (NYSE:BHC) has announced the launch of Fraxel FTX™, the next generation of skin resurfacing technology, at the ASLMS 2025 Conference in Orlando. The product will be initially rolled out to US dermatologists and aesthetic professionals, with global expansion planned in coming months.

The new Fraxel FTX™ features dual wavelength fractional laser technology (1550nm and 1927nm), targeting both superficial and deeper skin layers. Key improvements include:

• 20% reduction in handpiece weight and size with integrated cooling
• Intelligent Optical Tracking® with AccuTRAC™ for efficient treatment delivery
• Redesigned console with integrated arm
• New color touch screen interface for personalized treatments

The device is indicated for various dermatological procedures including skin resurfacing, treatment of dyschromia, actinic keratosis, melasma, wrinkles, and scars.

Positive

• Launch of next-generation skin resurfacing technology expanding product portfolio
• Improved technical specifications with 20% reduction in handpiece size
• Planned global market expansion beyond US

Negative

• None.

Insights

Medical Technology Expert

Bausch Health's Fraxel FTX represents incremental improvements to established skin resurfacing technology rather than revolutionary advancement in aesthetic devices.

The new Fraxel FTX maintains the core dual wavelength technology (1550nm and 1927nm) that has established Fraxel as a recognized brand in fractional laser therapy, while introducing several engineering refinements. The 20% reduction in handpiece weight and size addresses practitioner fatigue during lengthy procedures, while the integrated cooling technology targets patient comfort issues that have been barriers to treatment compliance.

The AccuTRAC technology for optical tracking represents an efficiency improvement that could increase throughput in busy aesthetic practices, potentially improving the device's return-on-investment metrics for practitioners. However, it's worth noting that the device's fundamental clinical applications remain unchanged - it's still indicated for the same conditions including dyschromia, cutaneous lesions, actinic keratosis, melasma, periorbital wrinkles, acne scars, and surgical scars.

From a competitive standpoint, these refinements appear designed to keep the Fraxel platform contemporary in a crowded aesthetic device market rather than establish new treatment capabilities. The ergonomic improvements and interface redesign address practical usability concerns that influence purchasing decisions among dermatologists and plastic surgeons but don't fundamentally change patient outcomes compared to previous generations.

Financial Analyst

Fraxel FTX launch represents standard product lifecycle management for Bausch's aesthetics division with clear financial impact indicators.

The launch of Fraxel FTX represents a standard product refresh for Bausch Health's Solta Medical business unit. The timing of the launch at the American Society for Laser Medicine & Surgery Conference follows industry norms for maximizing exposure to the target customer base of dermatologists and plastic surgeons. While the product incorporates several engineering improvements, the announcement lacks specific market projections or pricing information that would help quantify potential revenue impact.

The announcement indicates a phased rollout strategy, beginning with the US market and expanding globally "in the coming months." This suggests a gradual revenue ramp rather than an immediate significant contribution to quarterly results. The decision to maintain the established Fraxel branding while adding enhancements indicates Bausch is leveraging existing market recognition rather than attempting to create an entirely new product category.

Without details on unit economics, pricing strategy, or projected adoption rates, it's difficult to determine how meaningful this launch will be to Bausch Health's overall financial performance. The improvements appear focused on practitioner efficiency and comfort, which may help maintain competitive positioning but don't necessarily indicate opportunities for premium pricing or market expansion beyond existing Fraxel users.

The next generation of skin resurfacing technology will debut at the ASLMS 2025 Conference

LAVAL, QC / ACCESS Newswire / April 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, announced today Fraxel FTX™ will launch at the American Society for Laser Medicine & Surgery, Inc. (ASLMS) 2025 Annual Conference on April 25 in Orlando, FL. This event begins the rollout of Fraxel FTX™ to dermatologists, plastic surgeons, and other licensed aesthetic professionals across the United States, with plans to expand globally in the coming months.

Fraxel^® is a leading treatment in skin rejuvenation, addressing common skin concerns such as sun damage, wrinkles, acne scars, and pigmentation irregularities. With the introduction of Fraxel FTX™, the next generation of skin resurfacing technology, Bausch Health is setting a new standard in laser skin resurfacing. Designed to offer an even more precise, efficient, and comfortable treatment experience, this next generation product provides dermatologists and aesthetic professionals with advanced tools and is designed to deliver noticeable results after a single treatment in all skin types.

"We are pleased to unveil Fraxel FTX™ at the ASLMS 2025 Conference," said Thomas J. Appio, CEO of Bausch Health. "This improved technology marks a significant milestone in our commitment to advancing aesthetic medicine and enhancing the patient experience. Fraxel FTX™ embodies our dedication to providing healthcare professionals with the cutting-edge tools they need to help deliver exceptional care."

"Fraxel FTX™ retains its trusted, proven laser technology offering customized treatments to deliver noticeable results, while combining a modern design, ergonomic enhancements, and efficiency to support today's aesthetic practices," said Jiny Kim, Senior Vice President, Solta Medical, Bausch Health.

Key Features and Benefits of Fraxel FTX™:

• Dual Wavelength Fractional Laser: Fraxel FTX™ utilizes a highly refined fractional laser system that targets aging and sun-damaged skin, leaving surrounding healthy tissue intact to promote rapid healing. The 1550 nm erbium-glass laser and 1927 nm thulium laser treat superficial and deeper skin layers.

• Redesigned Ergonomic Handpiece: Featuring a 20% reduction in weight and size and new integrated cooling technology, Fraxel FTX™ is designed for patient comfort during treatment.

• Visible Results with Minimal Downtime: Patients can expect noticeable improvements in skin texture, tone, and clarity with minimal disruption to their daily routines.

• Fast Tracking Experience: Intelligent Optical Tracking^® with AccuTRAC™ provides efficient and consistent treatment delivery utilizing patented technology for efficient firing of the laser.

• Redesigned Console: A modern design with an integrated arm and cable assembly.

• Refreshed User Interface: The redesigned color touch screen and user interface are designed for flexible, personalized treatment settings, catering to aesthetic goals, as well as common skin concerns due to sun damage and aging.

With the launch of Fraxel FTX™, Solta Medical continues to lead the industry in innovation, providing solutions that aim to help practitioners deliver best-in-class results while improving patient satisfaction.

For more information about Fraxel FTX™ and other Solta Medical products, please visit www.soltamedical.com.

INDICATIONS

The Fraxel FTX™ Laser System is indicated for:

• Fraxel^® 1550 nm wavelength is indicated for dermatological procedures requiring the coagulation of soft tissue; skin resurfacing procedures; treatment of dyschromia and cutaneous lesions, such as, but not limited to lentigos, solar lentigos, actinic keratosis, and melasma; and treatment of periorbital wrinkles, acne scars, and surgical scars.

• Fraxel^® 1927 nm wavelength is indicated for dermatological procedures requiring the coagulation of soft tissue; treatment of actinic keratosis; treatment of pigmented lesions, specifically lentigos, solar lentigos, and ephelides.

IMPORTANT SAFETY INFORMATION

Contraindications

• Do not use on any patient who is ineligible for general surgery.

• Pre-screening should include, but not be limited to:

  • Predisposition to keloid formation or excessive scarring.

  • Changes following surgery.

  • Skin indentations and textural changes following surgery.

  • Systemic steroids (e.g. prednisone, dexamethasone), which should be rigorously avoided prior to and throughout the course of treatment.

  • Patients undergoing isotretinoin acne treatment or with drugs in a similar class.

• Medical judgement should be used when treating patients with a predisposition to post inflammatory hyperpigmentation (PIH).

Warnings and Cautions

• Protective eyewear or goggles should be worn by any patient, operator and assistant.

• Medical judgement should be used when treating patients with certain medical conditions.

• Improper use of Fraxel^® may cause personal injury or damage to the system.

Adverse Events

• The following may be associated with Fraxel^® laser treatment: Blistering and burns; Temporary or permanent skin discoloration; Eye injury; Infection; Keloid formation; Prolonged redness; Scarring; Delayed wound healing / skin textural changes and Temporary bruising.

The Fraxel FTX™ Laser System is Rx Only. See the Operator Manual for detailed directions, proper use, and full risk and safety information. For additional product information see www.fraxel.com/hcp.

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.
To learn more about the Fraxel FTX™ and how it can benefit your practice, contact Solta Medical.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our aesthetic business, Solta Medical, is a global leader in the aesthetics market, whose vision is to develop and support trusted aesthetic brands that provide value to our customers and patients. More information about Solta Medical can be found at www.solta.com. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642 (toll free)

Media Contact:
Katie Savastano
corporate.communications@bauschhealth.com
(908) 569-3692

SOURCE: Bausch Health Companies Inc.

View the original press release on ACCESS Newswire

FAQ

What are the main features of Bausch Health's new Fraxel FTX laser system (BHC)?

Fraxel FTX features dual wavelength fractional lasers (1550nm and 1927nm), 20% lighter handpiece, integrated cooling, Intelligent Optical Tracking®, and a modernized interface for personalized treatments.

What skin conditions can the new Fraxel FTX by Bausch Health (BHC) treat?

Fraxel FTX treats sun damage, wrinkles, acne scars, pigmentation irregularities, dyschromia, actinic keratosis, melasma, and surgical scars.

When will Bausch Health's Fraxel FTX (BHC) be available internationally?

After its US launch at ASLMS 2025 Conference, Bausch Health plans to expand Fraxel FTX globally in the coming months.

What are the safety considerations for Bausch Health's Fraxel FTX treatment (BHC)?

Key safety considerations include wearing protective eyewear, avoiding use with systemic steroids or isotretinoin, and potential risks like temporary redness, bruising, or skin discoloration.